Figure 4
From: An epigenetic vaccine model active in the prevention and treatment of melanoma
Anti-tumor immunity generated by TSA-treated apoptotic B16 cells. A) Kaplan-Meier plot of B6 mice (10 mice/group) vaccinated s.c. with magnetically separated TSA-treated (500 nM for 48 h) apoptotic (~99% an+), non-apoptotic (>85% an-), mixed (50% an+ with 50% an-) or H2O2-treated (10 mM for 4 h) apoptotic (~99% an+) B16 (1 × 105 cells) and observed for tumor-free survival. Control mice received untreated B16 cells. B) Tumor-free mice, 3 weeks after vaccination with TSA-treated apoptotic (n = 10), non-apoptotic (n = 8), mixed (n = 8) or H2O2-treated apoptotic (n = 10) B16 cells were re-challenged with untreated B16 (1 × 105 cells) s.c. in the opposite side of the trunk and observed subsequently for another 6 weeks. The data are presented as the percentage of tumor-free mice after tumor challenge.